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Abstract
Background: Evidence suggests that both green tea polyphenols (GTP) and Tai Chi (TC) exercise may benefit bone
health in osteopenic women. However, their safety in this population has never been systematically investigated. In
particular, there have been hepatotoxicity concerns related to green tea extract. This study was to evaluate the
safety of 24 weeks of GTP supplementation combined with TC exercise in postmenopausal osteopenic women,
along with effects on quality of life in this population.
Methods: 171 postmenopausal women with osteopenia were randomly assigned to 4 treatment arms for 24
weeks: (1) Placebo (500 mg starch/day), (2) GTP (500 mg GTP/day), (3) Placebo + TC (placebo plus TC training at 60
min/session, 3 sessions/week), and (4) GTP + TC (GTP plus TC training). Safety was examined by assessing liver
enzymes (aspartate aminotransferase, alanine aminotransferase), alkaline phosphatase, and total bilirubin at baseline
and every 4 weeks. Kidney function (urea nitrogen and creatinine), calcium, and inorganic phosphorus were also
assessed at the same times. Qualify of life using SF-36 questionnaire was evaluated at baseline, 12, and 24 weeks. A
mixed model of repeated measures ANOVA was applied for analysis.
Results: 150 subjects completed the study (12% attrition rate). The compliance rates for study agents and TC
exercise were 89% and 83%, respectively. Neither GTP supplementation nor TC exercise affected liver or kidney
function parameters throughout the study. No adverse event due to study treatment was reported by the
participants. TC exercise significantly improved the scores for role-emotional and mental health of subjects, while
no effect on quality of life was observed due to GTP supplementation.
Conclusions: GTP at a dose of 500 mg/day and/or TC exercise at 3 hr/week for 24 weeks appear to be safe in
postmenopausal osteopenic women, particularly in terms of liver and kidney functions. TC exercise for 24 weeks (3
hr/wk) significantly improved quality of life in terms of role-emotional and mental health in these subjects.
ClinicalTrials.gov identifier: NCT00625391.
Background
In a recent comprehensive review [1], we suggest that
tea and its bioactive components might reduce bone
fracture risk by benefiting bone mineral density (BMD)
and supporting osteoblastic activities while suppressing
osteoclaistic activities, possibly due to their antioxidant
and/or anti-inflammatory functions. Among different
types of tea, green tea polyphenols (GTP, extract of
green tea) has shown its osteo-protective effects by
decreasing oxidative stress [2,3], increasing activity of
antioxidant enzymes [2], and decreasing expression of
proinflammatory mediators in rodent models [3]. How-
ever, limited information is available on the protective
effect of consumption of tea or its bioactive components
(e.g., GTP) on bone health in postmenopausal women.
On the other hand, Tai Chi (TC), a form of mind-body,
moderate-intensity, aerobic and muscular fitness exer-
cise, has also shown to potentially benefit bone health
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any medium, provided the original work is properly cited.[4-7]. However, there is limited information based on
systematic study of TC’s effect on bone health in post-
menopausal women with low bone mass. Therefore, the
long-term goal of the study is to investigate the effect of
GTP and TC exercise on bone health in the targeted
population. This paper focuses on the safety and impact
on quality of life associated with this combined inter-
vention. Results of bone, inflammation and oxidative
stress parameters will be reported in a separate paper.
Legislation in use of complementary and alternative
medicine (i.e., herbal/dietary supplement) is not uni-
form, even lacking in many countries. In the US, green
tea extract is labeled as a dietary supplement which
does not seem to require pre-clinical tests, and its tradi-
tional use proves not to be harmful in the specified con-
dition of use [8]. Although green tea has been a popular
beverage for centuries, a systemic review by the recent
United States Pharmacopeia (USP) of 216 case reports
on green tea products revealed 34 reports concerning
liver damage [9]. Among them, 27 reports were categor-
ized as possible causality and 7 reports as probable caus-
ality. Based on this review, the USP Dietary Supplement
Information Expert Committee determined that when
dietary supplement products containing green tea
extract are used and formulated appropriately, the Com-
mittee is unaware of significant safety issues that would
prohibit monograph development. A caution statement
needs to be included in the labeling section [9].
On the other hand, based on published hepatotoxicity
episodes, Mazzanti et al. [10] concluded that there can
be no longer a reasonable doubt that ingestion of con-
centrated extracts of green tea and infusions of green
tea itself poses a real and growing risk to liver health.
The hepatotoxicity is probably due to (-)-epigallo-cate-
chin gallate or its metabolites which, under particular
conditions related to the patient’s metabolism, can
induce oxidative stress in the liver. In a few cases, toxi-
city related to concomitant medications could also be
involved [10].
The above evidence suggests that it is important to
assess safety issues in conducting a long-term clinical
study involving green tea extract as a treatment. How-
ever, most of the published green tea clinical studies
were either short-term (≤ 12 weeks) [11-13], with a
longer study period but little or limited information on
safety data related to liver function [14,15], or relatively
small sample sizes [11-15]. The detailed safety informa-
tion is important because for all of the interest in clini-
cal studies using green tea as study agents, lacking such
information hinders the research development. The pre-
sent work is the first GTP safety report on liver and kid-
ney functions based on a larger sample size in a 24-week
placebo-controlled and randomized clinical trial.
Tai Chi has been investigated in many clinical studies,
and is generally considered a safe intervention/treatment
in population with various health issues [16]. However,
no study evaluated the effect of TC in conjunction with
GTP supplementation on liver and kidney function in
any study population. It is not clear if Tai Chi exercise
would interact with GTP to attenuate green tea related
toxicity in our study subjects. Such safety data are
important to future clinical studies using GTP and/or
Tai Chi as study treatment.
Therefore, the objective of this paper is to evaluate the
safety of 24 weeks of GTP supplementation combined
with TC exercise in postmenopausal osteopenic women.
In addition to safety, the effects of treatment arms on
quality of life (as assessed by SF-36 questionnaires) are
also reported.
Methods
Study participants
Postmenopausal women were recruited primarily
through flyers, local TV, radios, newspaper, municipal
community centers and clinics to participate in this
study. The complete study protocol has been reported
in detail previously [17] and only a brief description is
provided here.
Inclusion criteria were (i) postmenopausal women (at
least 2 years after menopause) with osteopenia (mean
lumbar spine and/or hip bone mineral density (BMD)
T-score between 1 and 2.5 standard deviation (SD)
below the young normal sex-matched areal BMD of
the reference database) [12], (ii) normal function of
thyroid (thyroid-stimulating hormone (TSH) > 0.3 and
< 5.0 mU/L), liver (bilirubin ≤ 2.0 mg/dL, aspartate
aminotransferase (AST)/alanine aminotransferase
(ALT) < 3 × upper limit of normal), and kidney
(serum creatinine (Crt) ≤ 2.0 mg/dL, blood urea nitro-
gen (BUN) < 1.5 times), (iii) serum alkaline phospha-
tase (ALP) (33 - 130 U/L), calcium (Ca) (8.6 - 10.2
mg/dL), and inorganic phosphorus (Pi) (2.5 - 4.5 mg/
dL) were within normal ranges, (iv) and serum 25-
hydroxy vitamin D (25(OH)D) ≥ 20 ng/mL.
Women were excluded if they (i) had a disease condi-
tion or were on medication known to affect bone meta-
bolism, (ii) had a history of cancer except for treated
superficial basal or squamous cell carcinoma of the
skin, (iii) had uncontrolled intercurrent illness or physi-
cal condition that would be a contraindication to exer-
cise, (iv) had depression, cognitive impairment, or (v)
were unwilling to accept randomization. Written
informed consent was obtained from all the participants
before enrollment. The study was approved by the
Texas Tech University Health Sciences Center Institu-
tional Review Board.
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This was a 24-week, placebo-controlled, randomized
intervention trial to investigate the effects of GTP and
TC on bone parameters. Participants were randomly
assigned to one of the four treatment groups:
▪ Placebo group: medicinal starch 500 mg daily
▪ GTP group: GTP 500 mg daily
▪ Placebo + TC group: medicinal starch 500 mg
daily and 24-move simplified Yang-style TC training
(60 minutes per session, 3 sessions per week)
▪ GTP + TC group: GTP 500 mg daily and 24-move
simplified Yang-style TC training (60 minutes per
session, 3 sessions per week)
Medicinal starch and GTP study agents were supplied
by Zhejiang Yuxin Pharmaceutical Co., Ltd., China (US
FDA IND number 77,470). The main GTP components
were 99.25% pure, with 46.5% of epigallocatechin-3-gal-
late (EGCG), 21.25% of epigallocatechin (ECG), 10% of
epicatechin (EC), 7.5% of epicatechin-3-gallate (EGC),
9.5% of gallocatechin gallate (GCG), and 4.5% of cate-
chin. The daily dose of GTP or placebo material was
divided into two capsules (250 mg each). During the
24-week intervention, all participants were provided
with 500 mg elemental calcium and 200 IU vitamin D
(as cholecalciferol) daily.
Randomization and blinding
To ensure comparable distribution across treatment
arms, eligible participants were stratified before rando-
mization by a fixed randomized scheme based on age (≥
65 or < 65 years old), history of green tea consumption,
and history of mind-body exercise. Both the study parti-
cipants and investigators responsible for the day-to-day
operation and data analyses were blinded to the GTP/
placebo group status.
Measurements
Medical history, physical activity level, depression
(mood), and cognitive impairment assessment were col-
lected at the time of enrollment. The depression (mood)
assessment was measured by the Yesavage self-rated
Geriatric Depression Score [18]. BMD was determined
at baseline for the screening purpose by dual energy X-
ray absorptiometry (DEXA) (Norland Excel X-Ray Bone
Densitometer). Also at baseline for screening purposes
only, overnight fasting blood and urine samples were
collected for the measurement of concentrations of
serum 25(OH)D and TSH by a certified diagnostic
laboratory (Quest Diagnostics, Dallas, TX).
Laboratory blood chemistry parameters, including
ALP, BUN, bilirubin (Bil), AST, ALT, Ca, Pi, and Crt
were assessed in overnight fasting blood samples taken
at baseline and every 4 weeks throughout the study per-
iod. All samples were processed and analyzed in a certi-
fied diagnostic laboratory (Quest Diagnostic Laboratory,
Dallas, TX).
General health status was measured with the Medical
Outcomes Study 36-item short form Health Survey
(SF-36, version 2) at baseline, 12 and 24 weeks of study.
SF-36 has been reported to have good validity, internal
consistency, and reliability in the assessment of physical
and mental health status of subjects and their progression
[19,20]. The SF-36 consists of eight dimensions of health
(physical function, bodily pain, general health, vitality,
mental health, social function, and role of physical and
emotional health) in the conduct of daily activity [21].
Adverse event monitoring
In the course of the 24-week clinical trial, adverse events
associated with study agents were self-reported by the
participants, and by monitoring liver enzyme activities,
AST and ALT in particular, through blood analysis. Par-
ticipants in the TC exercise groups (placebo + TC and
the GTP + TC groups) were also queried about any
adverse events due to TC during TC training sessions.
They were also encouraged to self-report any adverse
events by telephone. All observed and self-reported
adverse events, regardless of suspected causal relation-
ship to the study treatments, were recorded on the
adverse event form throughout the study.
Compliance
Adherence/compliance of GTP or placebo study agents
was determined as the percentage of all capsules of GTP
or placebo capsules ingested throughout the study per-
iod. Compliance of TC classes was assessed by TC class
attendance record for each TC session.
Statistical analysis
For this longitudinal study, a model of repeated mea-
surements with random effect error terms was used
with “intention-to-treat analysis” for missing data, if
applicable. Statistical software SPSS 16.0 (Clicago, IL,
USA) was employed to conduct the analyses, controlling
for the within subject correlation. First, participant char-
acteristics were compared to detect any difference
among the four groups at baseline. Second, changes in
the measurements between baseline and the follow-ups
were analyzed. For between-group differences over time,
a repeated measure ANOVA was conducted and con-
trolled for within-subject correlation. The two treatment
factors are GTP (vs. placebo) and TC (vs. no TC).
Third, the characteristics of participants who dropped
out were compared with those of the participants who
stayed for the entire study period in order to detect
potential biases.
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Participants
A total of 1065 patients were prescreened. Among them,
171 were qualified and randomized, and 150 completed
the 24-week study (Figure 1). Seven (16%) participants in
the Placebo arm, 8 (17%) in the GTP arm, 5 (12%) in the
Placebo + TC arm, and 1 (3%) in the GTP + TC arm
withdrew before the end of the study, due to accidental
fall (1 subject), relocation (2 subjects), time conflicts (6
subjects), lost to follow-up (5 subjects), and lost interest
(7 subjects). Baseline characteristics were similar among
different treatment groups (Table 1). No statistically sig-
nificant differences between the subjects who withdrew
from the study and those who completed the study were
observed in any parameter listed in Table 1. All subjects
were instructed to maintain their pre-existing physical
activity, dietary habits, and medications, if any, through-
out the study. Based on the results of pill count, the
compliance rate was 89% for both GTP and placebo
capsules. The compliance rate for TC classes was 83%.
Safety
At the baseline, there was no significant difference in
any of the blood chemistry parameters among all treat-
ment groups (Table 2). Based on the results of ANOVA,
the levels of serum AST and ALT (indicators of liver
functions) were not affected by either GTP or TC inter-
vention during the 24-week study period (Table 2).
Similarly, neither GTP supplementation nor TC exercise
influenced serum BUN in subjects (Table 2). On the
other hand, throughout the course of the 24-week inter-
vention, there were significant decreasing trends in
levels of serum Bil, ALP, Crt, Ca, and Pi over time with
different magnitude in each treatment arm. However, in
analyzing interaction between the time factor and the
two treatment factors (GTP and TC), these parameters
Figure 1 Study flow chart.
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Variables Placebo GTP Placebo+TC GTP+TC P value
Number 44 47 42 38
Age [y], mean ± SD 57.6 ± 7.5 56.5 ± 5.5 58.3 ± 7.7 57.6 ± 6.7 NS
Years after menopause 12.5 ± 8.4 11.2 ± 8.3 14.2 ± 11.1 11.4 ± 9.1 NS
Height [cm] 162.8 ± 7.8 162.7 ± 5.4 161.9 ± 6.2 164.1 ± 7.1 NS
Weight [kg] 77.4 ± 15.4 74.5 ± 11.9 74.1 ± 12.1 72.9 ± 14.6 NS
Body mass index [kg/m
2] 29.2 ± 6.1 28.1 ± 4.4 28.3 ± 4.9 27.1 ± 5.8 NS
Bone mineral density [T-score]
Femoral Neck -1.50 ± 0.62 -1.51 ± 0.64 -1.64 ± 0.56 -1.69 ± 0.59 NS
Trochanter -1.05 ± 0.81 -1.10 ± 0.70 -1.27 ± 0.62 -1.29 ± 0.71 NS
Total spine -0.74 ± 0.56 -0.75 ± 0.67 -0.95 ± 0.65 -0.97 ± 0.51 NS
L1-L4 -0.60 ± 0.85 -0.53 ± 1.09 -0.65 ± 0.76 -0.75 ± 0.83 NS
Serum 25 (OH)D [ng/mL] 32.5 ± 8.4 36.2 ± 11.0 31.5 ± 11.5 30.1 ± 6.6 NS
Serum PTH [pg/mL] 47.8 ± 20.1 45.6 ± 22.5 48.2 ± 22.3 47.2 ± 27.1 NS
Serum TSH [mIU/L] 2.50 ± 1.38 2.09 ± 1.13 2.38 ± 0.94 2.56 ± 1.30 NS
General health questions [n (%)]
General health rated “good” 35 (79.5) 38 (80.9) 38 (90.4) 30 (78.9) NS
Height decrease with age 3 (6.8) 10 (21.2) 7 (16.6) 9 (23.6) NS
Broken bone as adult 9 (20.4) 13 (27.6) 7 (16.6) 14 (36.8) NS
History of osteopenia 9 (20.4) 8 (17.0) 9 (21.4) 9 (23.9) NS
Family history of low bone mass 19 (36.3) 24 (51.0) 13(30.9) 23 (60.5) NS
History of osteoarthritis 9 (20.4) 5 (10.6) 4 (9.5) 4 (10.5) NS
Severe joint or muscle pain 16 (36.3) 12 (25.5) 9 (21.4) 9 (23.6) NS
Back or leg pain 11 (25.0) 12 (25.5) 4 (9.5) 5 (13.1) NS
History of diabetes 1 (2.3) 5 (10.6) 6 (14.2) 3 (7.8) NS
History of hypertension 13 (29.5) 9 (19.1) 10 (23.8) 8 (21.0) NS
Physical activity profiles, mean ± SD
Exercise frequency [sessions/week] 2.4 ± 2.1 2.0 ± 2.1 1.8 ± 2.0 1.9 ± 2.0 NS
Exercise time [min/session] 22 ± 19 23 ± 21 29 ± 46 23 ± 22 NS
Mood assessment
§, mean ± SD 5.7 ± 5.2 5.9 ± 4.9 5.9 ± 5.6 6.3 ± 4.2 NS
Lifestyle profiles [n (%)]
History of steroid use 9 (20.4) 7 (14.8) 8 (19.0) 12 (31.5) NS
Antidepressant medication use 20 (40.5) 19 (40.4) 17 (40.4) 18 (47.3) NS
Estrogen/HRT use 9 (20.4) 10 (21.2) 10 (23.8) 7 (18.4) NS
Calcium/Vitamin D use 22 (50) 23 (48.9) 21 (50) 17 (44.7) NS
Trouble sleeping 16 (36.4) 17 (36.1) 16 (38.1) 12 (31.5) NS
Current cigarette smoking 2 (4.5) 2 (4.2) 2 (4.7) 1 (2.6) NS
Alcohol consumption 23 (52.2) 18 (38.2) 18 (42.8) 21 (55.2) NS
Tea consumption 26 (59.1) 23 (48.9) 22 (52.3) 27 (71.0) NS
Coffee consumption 28 (63.6) 34 (72.3) 28 (66.6) 24 (65.5) NS
Soda consumption 28 (63.6) 29 (65.9) 23 (54.7) 27 (71.1) NS
Juice consumption 12 (27.2) 22 (46.8) 19 (45.2) 21 (55.2) NS
GTP, green tea polyphenols; TC, Tai Chi; 25(OH)D, 25-hydroxy-vitamin D; SD, standard deviation; PTH, parathyroid hormone; TSH, thyroid stimulating hormone;
HRT, hormone replacement treatment; NS, not significant (P > 0.005).
§Mood assessment was performed by the Yesavage self-rated Geriatric Depression Score.
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osteopenic women
Treatment groups P (ANOVA)
Variables Placebo GTP Placebo+TC GTP+TC Time Time × GTP Time × TC Time × GTP × TC
Serum AST, U/L (reference range: 10-35 U/L) 0.431 0.678 0.599 0.437
Baseline 19.8 ± 4.3 21.2 ± 6.3 21.2 ± 5.9 19.3 ± 4.3
4 week 19.8 ± 4.6 20.9 ± 4.8 21.4 ± 6.1 19.8 ± 4.5
8 week 20.5 ± 5.7 22.1 ± 6.7 21.4 ± 5.8 20.8 ± 5.8
12 week 19.9 ± 5.1 20.9 ± 5.8 22.1 ± 7.3 20.4 ± 5.1
16 week 19.8 ± 4.4 22.6 ± 7.4 20.9 ± 6.9 20.3 ± 5.1
20 week 19.3 ± 3.7 21.8 ± 6.9 22.7 ± 12.3 19.3 ± 3.5
24 week 19.3 ± 4.2 20.2 ± 6.2 21.1 ± 7.2 20.3 ± 6.1
Serum ALT, U/L (reference range: 6-60 U/L) 0.454 0.955 0.893 0.235
Baseline 16.9 ± 5.5 20.4 ± 10.1 19.0 ± 7.0 18.0 ± 6.9
4 week 16.9 ± 4.8 19.2 ± 7.9 19.5 ± 6.6 18.5 ± 7.2
8 week 17.4 ± 7.7 21.2 ± 10.9 20.4 ± 7.8 19.2 ± 9.9
12 week 17.1 ± 6.4 19.9 ± 8.2 19.2 ± 9.0 19.9 ± 9.1
16 week 17.1 ± 5.8 21.8 ± 11.7 19.7 ± 6.9 19.0 ± 8.1
20 week 16.6 ± 5.2 21.6 ± 11.3 20.3 ± 9.4 18.1 ± 5.0
24 week 16.9 ± 6.3 19.1 ± 9.9 18.5 ± 5.7 19.5 ± 10.2
Serum Bil, mg/dL (reference: 0.2-1.2 mg/dL) 0.001 0.799 0.493 0.060
Baseline 0.58 ± 0.19 0.55 ± 0.19 0.65 ± 0.25 0.64 ± 0.26
4 week 0.58 ± 0.23 0.59 ± 0.23 0.67 ± 0.27 0.63 ± 0.22
8 week 0.57 ± 0.17 0.57 ± 0.21 0.68 ± 0.28 0.59 ± 0.25
12 week 0.58 ± 0.16 0.53 ± 0.22 0.59 ± 0.30 0.60 ± 0.31
16 week 0.58 ± 0.18 0.54 ± 0.18 0.62 ± 0.23 0.55 ± 0.22
20 week 0.56 ± 0.21 0.56 ± 0.23 0.64 ± 0.28 0.57 ± 0.21
24 week 0.56 ± 0.20 0.54 ± 0.20 0.60 ± 0.17 0.56 ± 0.23
Serum ALP, U/L (reference range: 33-130 U/L) < 0.001 0.925 0.149 0.438
Baseline 75.3 ± 18.6 84.1 ± 19.9 81.6 ± 20.1 86.8 ± 25.2
4 week 77.1 ± 17.7 85.6 ± 20.5 81.5 ± 23.4 86.8 ± 23.1
8 week 75.2 ± 17.7 83.1 ± 22.9 85.2 ± 26.0 88.6 ± 25.4
12 week 75.1 ± 18.0 83.2 ± 19.3 82.9 ± 24.8 87.7 ± 24.2
16 week 71.6 ± 18.1 84.4 ± 22.2 80.8 ± 22.9 83.9 ± 21.1
20 week 74.7 ± 19.3 84.6 ± 20.7 83.4 ± 22.1 87.0 ± 22.6
24 week 72.3 ± 17.3 82.5 ± 20.3 80.9 ± 22.5 83.5 ± 20.7
Serum Crt, mg/dL (reference range: 0.5-1.3 mg/dL) 0.001 0.230 0.605 0.884
Baseline 0.80 ± 0.13 0.82 ± 0.11 0.78 ± 0.14 0.79 ± 0.09
4 week 0.82 ± 0.17 0.80 ± 0.10 0.79 ± 0.13 0.79 ± 0.10
8 week 0.80 ± 0.13 0.80 ± 0.12 0.80 ± 0.23 0.80 ± 0.11
12 week 0.82 ± 0.14 0.81 ± 0.11 0.80 ± 0.14 0.80 ± 0.10
16 week 0.81 ± 0.13 0.83 ± 0.10 0.79 ± 0.13 0.82 ± 0.10
20 week 0.82 ± 0.14 0.82 ± 0.11 0.81 ± 0.14 0.80 ± 0.11
24 week 0.79 ± 0.13 0.80 ± 0.11 0.77 ± 0.12 0.79 ± 0.09
Serum BUN, mg/dL (reference range: 7-25 mg/dL) 0.178 0.158 0.118 0.433
Baseline 15.1 ± 3.1 15.8 ± 3.8 15.6 ± 4.1 15.6 ± 3.7
4 week 16.7 ± 4.9 15.8 ± 3.4 16.4 ± 4.3 15.6 ± 4.1
8 week 15.8 ± 3.8 14.7 ± 3.4 15.6 ± 3.7 15.6 ± 3.7
12 week 16.4 ± 3.4 15.4 ± 3.9 15.8 ± 4.6 15.2 ± 3.5
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across all the treatment arms (Table 2).
Four participants reported side/adverse effects during
the study. One subject in the Placebo arm experienced
nausea and diarrhea several times. One subject in the
GTP arm had elevated AST and ALT levels, possibly
due to concomitant medications for cold symptoms
(Ibuprofen 400 mg daily for 9 days), lowering cholesterol
(Lipitor 20 mg daily) and hypertension (Metoprolol 25
mg daily). After discontinuation of the medication for
cold symptoms, this patient’s serum AST and ALT fell
back to the normal range. One subject in the Placebo +
TC arm reported having retinal bleeding on a non-exer-
cise day, probably due to her uncontrolled high blood
pressure and blood glucose, along with a family history
of retinal bleeding. Another subject in the Placebo + TC
arm reported having a broken wrist on a non-exercise
day, due to an accidental fall. These four reports, as
judged by the safety monitoring team, were unlikely
related to the study protocol.
No adverse event due to TC was observed or reported
in this study. There were only sporadic complaints
about muscle soreness during the first two weeks.
Quality of life
Data demonstrating the effects of GTP and TC on quality
of life, including all 8 domains, in postmenopausal
osteopenic women are presented in Table 3. At baseline,
there was no significant difference in any domain of qual-
ity of life among all 4 treatment groups. Throughout the
course of the 24-week intervention, there was no statisti-
cally significant change in any domain with time in all
treatment groups, except that scores for physical function
decreased with time (P < 0.001). However, when taking
into account the interaction between time and the two
treatment factors (GTP and TC), scores for physical
function were not statistically different. Compared to
those in the non-TC (Placebo and GTP) groups, subjects
in the TC (Placebo + TC and GTP + TC) groups showed
significant improvement in their scores for role-emo-
tional (P = 0.036) and mental health (P = 0.003) after the
24-week intervention (Table 3). There was no significant
difference in other domains of quality of life, including
role-physical, bodily pain, general health, vitality, and
social function (P > 0.05) (Table 3).
Discussion
There is generally very little clinical information on the
safety of long-term consumption of green tea extract
supplements. The limited number of published studies
were either short-term or with a small sample size, and
most of them were not randomized controlled trials.
This is the first placebo-controlled randomized study to
evaluate the safety of long-term ingestion of green tea
Table 2 Effect of green tea polyphenols supplementation and Tai Chi exercise on blood chemistry in postmenopausal
osteopenic women (Continued)
16 week 15.3 ± 3.6 15.9 ± 4.0 16.7 ± 3.6 15.9 ± 3.4
20 week 15.9 ± 3.7 16.4 ± 3.7 15.2 ± 3.5 15.3 ± 3.4
24 week 15.7 ± 3.7 15.7 ± 3.7 15.9 ± 5.1 15.3 ± 3.5
Serum Ca, mg/dL (reference range: 8.6-10.2 mg/dL) 0.005 0.721 0.076 0.883
Baseline 9.4 ± 0.4 9.4 ± 0.3 9.4 ± 0.2 9.5 ± 0.3
4 week 9.5 ± 0.4 9.4 ± 0.4 9.4 ± 0.3 9.4 ± 0.4
8 week 9.5 ± 0.5 9.4 ± 0.3 9.4 ± 0.3 9.5 ± 0.4
12 week 9.5 ± 0.4 9.4 ± 0.5 9.4 ± 0.3 9.4 ± 0.5
16 week 9.4 ± 0.4 9.4 ± 0.3 9.5 ± 0.4 9.5 ± 0.4
20 week 9.5 ± 0.4 9.3 ± 0.4 9.4 ± 0.3 9.5 ± 0.3
24 week 9.4 ± 0.4 9.3 ± 0.3 9.3 ± 0.3 9.3 ± 0.4
Serum Pi, mg/dL (reference range: 2.5-4.5 mg/dL) 0.001 0.547 0.027 0.825
Baseline 3.7 ± 0.5 3.6 ± 0.6 3.7 ± 0.5 3.7 ± 0.4
4 week 3.8 ± 0.5 3.6 ± 0.5 3.7 ± 0.5 3.7 ± 0.5
8 week 3.7 ± 0.5 3.6 ± 0.5 3.8 ± 0.5 3.8 ± 0.4
12 week 4.0 ± 0.9 3.7 ± 0.5 3.8 ± 0.5 3.8 ± 0.4
16 week 3.7 ± 0.5 3.7 ± 0.5 3.9 ± 0.5 3.8 ± 0.5
20 week 3.8 ± 0.4 3.7 ± 0.5 3.8 ± 0.5 3.7 ± 0.5
24 week 3.7 ± 0.4 3.6 ± 0.6 3.8 ± 0.5 3.7 ± 0.4
GTP, green tea polyphenols; TC, Tai Chi; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Bil, total bilirubin; ALP, alkaline phosphatase; Crt,
creatinine; BUN, blood urea nitrogen; Ca, calcium; Pi, inorganic phosphorus.
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Page 7 of 10extract in postmenopausal women. This study demon-
strated that supplementation of 500-mg GTP daily for
24 weeks did not cause any safety concern (Table 2)
with regard to liver function (in terms of AST, ALT, Bil,
and ALP levels) as well as kidney function (in terms of
Crt and BUN levels).
Considering a typical commercial decaffeinated green
tea bag that contains approximately 80-100 mg green
tea flavanols per serving [22], the GTP daily dose (500
mg with 99.25% purity) used in this study was approxi-
mately equivalent to beverage prepared by 5-6 commer-
cial decaffeinated tea bags. On the other hand, our
previous animal study showed that GTP supplementa-
tion through 0.5% GTP in drinking water benefited
bone remodeling in ovariectomized middle-aged rats [2].
This dose of GTP consumption by rats in that study
Table 3 Effect of green tea polyphenols supplementation and Tai Chi exercise on quality of life in postmenopausal
osteopenic women
Treatment groups P (ANOVA)
Domain Placebo GTP Placebo+TC GTP+TC Time Time ± GTP Time ± TC Time ± GTP TC
Physical function < 0.001 0.214 0.414 0.453
Baseline 77.7 ± 21.4 77.6 ± 21.7 78.4 ± 16.3 80.4 ± 19.1
12 week 72.9 ± 28.8 81.8 ± 21.2 80.9 ± 15.7 84.1 ± 15.6
24 week 65.9 ± 20.6 68.4 ± 20.4 68.1 ± 16.3 69.4 ± 16.4
Role-physical 0.136 0.477 0.578 0.466
Baseline 80.0 ± 34.7 78.4 ± 30.1 81.8 ± 33.2 84.6 ± 28.2
12 week 85.7 ± 28.6 83.8 ± 30.7 80.4 ± 36.4 86.8 ± 26.3
24 week 80.7 ± 31.6 89.2 ± 23.9 85.1 ± 28.5 89.7 ± 24.7
Bodily pain 0.703 0.679 0.947 0.791
Baseline 73.8 ± 19.2 73.2 ± 17.5 74.5 ± 17.3 76.6 ± 15.3
12 week 73.4 ± 19.3 74.2 ± 18.1 74.9 ± 16.5 76.2 ± 14.9
24 week 74.5 ± 18.4 73.9 ± 17.0 77.3 ± 16.4 76.1 ± 17.2
General health 0.168 0.676 0.917 0.114
Baseline 76.6 ± 16.5 72.9 ± 19.7 75.4 ± 16.2 76.4 ± 18.2
12 week 77.8 ± 13.6 75.1 ± 21.4 77.1 ± 16.4 77.3 ± 16.9
24 week 75.2 ± 16.0 76.0 ± 20.1 77.5 ± 16.2 76.5 ± 17.1
Vitality 0.064 0.305 0.576 0.160
Baseline 63.0 ± 20.7 58.0 ± 24.1 60.8 ± 23.0 64.7 ± 18.9
12 week 62.3 ± 22.4 59.5 ± 23.5 63.1 ± 21.7 67.9 ± 17.5
24 week 60.6 ± 19.7 64.2 ± 22.7 65.4 ± 22.7 68.7 ± 19.1
Social function 0.250 0.731 0.338 0.986
Baseline 89.3 ± 20.8 86.8 ± 20.2 85.1 ± 22.4 86.8 ± 16.6
12 week 88.6 ± 20.2 88.2 ± 20.8 87.5 ± 22.8 91.9 ± 14.7
24 week 85.7 ± 22.7 85.1 ± 22.4 86.1 ± 24.1 89.3 ± 18.2
Role-emotional 0.464 0.918 0.036 0.815
Baseline 87.6 ± 29.2 88.3 ± 25.1 77.5 ± 36.9 81.4 ± 30.9
12 week 89.5 ± 27.7 85.6 ± 31.0 81.1 ± 35.6 87.3 ± 30.7
24 week 85.7 ± 32.6 82.9 ± 33.0 88.3 ± 26.3 91.2 ± 20.6
Mental health 0.629 0.931 0.003 0.232
Baseline 80.2 ± 12.6 81.5 ± 11.5 77.4 ± 14.9 76.9 ± 15.7
12 week 80.8 ± 14.4 78.7 ± 14.3 78.3 ± 16.9 82.0 ± 10.8
24 week 78.6 ± 13.9 77.3 ± 17.1 81.3 ± 12.4 82.6 ± 10.0
Data represent mean ± standard deviation (SD).
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Page 8 of 10was comparable to the dosage employed in the present
study. GTP dosages similar to our study have been
adopted in study populations with different health
issues. However, the study periods were generally short
(up to 12 weeks) in most studies with the following two
exceptions. Matsuyama et al. [14] reported that 24
weeks of beverage ingestion containing catechin (576
mg daily) ameliorated serious obesity and cardiovascular
disease risk factors without raising any safety concerns
in obese Japanese children (aged 6-16 years). Janjua et
al. [15] reported that GTP supplementation (500 mg
with 70% catechin daily) for two years did not demon-
strate a significant benefit superior to placebo in
improving clinical or histological photoaging parameters
of women’s skin (aged 25 to 75 years). However, none
of these studies investigated GTP’s safety in terms of
possible liver and kidney damages through monthly
blood tests. Further, the sample sizes of these published
studies were small.
In this study, we observed decreasing trends in the
levels of serum Bil, ALP, Crt, Ca, and Pi over the study
period (Table 2). However, such trends disappeared
when analyzing interaction between the time factor and
the two treatment factors (GTP and TC), suggesting
possible body’s adaptation to intervention stimuli over
time.
In the present study, the four adverse events observed
in different treatment arms were judged as unlikely
related to the study protocol. Previous studies reporting
adverse events with green tea extract supplementation,
including acute liver failure in a few isolated case
reports [23-26], in controlled human intervention trials
[27,28], and in epidemiological studies suggested that
possible medication contamination and other unknown
factors may have contributed to hepatotoxicity [29].
Hepatotoxicity might also possibly be due to unusual
dosing protocols, such as fasting, or a genetic variation
(single nucleotide polymorphisms) in phase I and phase
II enzymes in some affected individuals [30,31].
No adverse event attributed to TC was observed or
reported in this study. This is in agreement with pre-
vious studies reported by us and others [16]. TC, featur-
ing gentle, slow and flowing movements, has been
c o n s i d e r e das a f ee x e r c i s ew i t hv e r yl o wr i s ko fi n j u r y .
As expected, TC did not influence any parameters
related to liver and kidney function, except for a
decreasing trend of serum Pi with time, which became
not significant considering interaction between time and
TC (Table 2). In addition, there was no interaction
between GTP supplementation and TC exercise on liver
and kidney function in the present study.
The present results show that 24 weeks of TC exercise
confers beneficial effects on postmenopausal women in
terms of improving their role-emotional and mental
health (Table 3). The favorable profiles of TC on mental
health in the present study are consistent with those
reported by Ko et al. [32] in healthy women, and by
Abbott et al. [33] in patients with tension headaches.
The positive impact of TC on the role-emotional
domain also agrees with findings by Abbott et al. [33].
On the other hand, after involving GTP treatment, the
interaction among time, GTP and TC was not signifi-
cant (P > 0.05) in the domain of either role-emotional
or mental health. Although time × TC did reach statisti-
cal significance, but time × GTP did not reach statistical
significance, therefore, resulting in no significance in the
results of time × GTP × TC.
This is the first study investigating the effect of GTP
supplementation on quality of life, and the result
showed no effect. There was also no evidence support-
ing that selenium supplementation benefited quality of
life in apparently healthy elderly (aged 60-74) in a dou-
ble-blind, placebo-controlled intervention [34]. Another
study found that vitamin E intake did not change quality
of life in patients with amyotrophic lateral sclerosis [35].
Although all these supplements (GTP, selenium, vitamin
E) are considered to be functional in protecting cells
from oxidative stress, these published studies along with
the present study seem to suggest no benefit of these
supplements in quality of life.
Conclusion
Supplementation of 500-mg GTP daily to postmenopau-
sal osteopenic women for 24 weeks did not cause any
adverse effects on liver and kidney function, as deter-
mined by blood test parameters, and had no influence
on quality of life (as assessed by SF-36 questionnaires).
TC exercise for 24 weeks (3 hr/wk) significantly
improved quality of life in terms of role-emotional and
mental health in these subjects. Based on our findings,
GTP at a dose of 500 mg per day and/or TC exercise at
3 hr/week for 24 weeks appear to be safe in postmeno-
pausal osteopenic women.
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